Real‐world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17‐gene genomic prostate score® (GPSTM) assay

Abstract

AbstractObjectivesDescriptive study focusing on real‐world utilization and characteristics of men with prostate cancer tested with the 17‐gene Genomic Prostate Score® (GPS™) assay by linking administrative claims and electronic health record (EHR) data with GPS results.MethodsThis retrospective, observational cohort study (January 1, 2013 to December 31, 2020) included men aged 40–80 years with localized prostate cancer claims, continuous enrollment in Optum's Integrated Claims data set, ≥1 day of EHR clinical activity, and a GPS result. Men were classified as undergoing definitive therapy (DT) (prostatectomy, radiation, or focal therapy) or active surveillance (AS). AS and DT distribution were analyzed across GPS results, National Comprehensive Cancer Network® (NCCN®) risk, and race. Costs were assessed 6 months after the first GPS result (index); clinical outcomes and AS persistence were assessed during the variable follow‐up. All variables were analyzed descriptively.ResultsOf 834 men, 650 (77.9%) underwent AS and 184 (22.1%) DT. Most men had Quan‐Charlson comorbidity scores of 1–2 and a tumor stage of T1c (index). The most common Gleason patterns were 3 + 3 (79.6%) (AS cohort) and 3 + 4 (55.9%) (DT cohort). The mean (standard deviation) GPS results at index were 23.2 (11.3) (AS) and 30.9 (12.9) (DT). AS decreased with increasing GPS result and NCCN risk. Differences between races were minimal. Total costs were substantially higher in the DT cohort.ConclusionsMost men with GPS‐tested localized prostate cancer underwent AS, indicating the GPS result can inform clinical management. Decreasing AS with increasing GPS result and NCCN risk suggests the GPS complements NCCN risk stratification.